Results 11 to 20 of about 9,914 (164)

Efficacy and tolerance of a novel topical TRPV‐1 channel antagonist in dogs with allergic pododermatitis

Veterinary Dermatology, Volume 34, Issue 6, Page 514-522, December 2023., 2023
Background – Pruritus is one of the most common reasons for dermatological consultations in the veterinary clinic. Treatment is normally multimodal and requires continuous monitoring and reassessment. New therapies are needed to broaden the therapeutic arsenal.
Xavier Serra Fabregat, Miguel Ángel de Pablo, Conchita Hernán‐Pérez, Elena Diéguez, Oliver Valero Coppin, Elsa Genové Corominas   +5 more
wiley   +1 more source

Modified rush venom immunotherapy in dogs with Hymenoptera hypersensitivity

Veterinary Dermatology, Volume 34, Issue 6, Page 532-542, December 2023., 2023
Background – Hymenoptera envenomation occurs frequently in people and dogs and can trigger anaphylaxis. Venom immunotherapy (VIT) is the only preventative treatment for Hymenoptera hypersensitivity and is indicated for people with severe adverse reactions to insect stings. Rush VIT is an accelerated VIT induction schedule performed in people.
Alexandra Moore, Amanda K. Burrows, Wayne S. Rosenkrantz, Rudayna M. Ghubash, Giselle Hosgood   +4 more
wiley   +1 more source

The safety of rush immunotherapy in the management of canine atopic dermatitis—230 cases

Veterinary Dermatology, Volume 34, Issue 5, Page 385-392, October 2023., 2023
Background – The duration of the induction phase of allergen‐specific immunotherapy conventionally is a period of several weeks, during which the volume of an allergen solution, administered by injection, is gradually increased until the maintenance dose is reached.
Tamara Weitzer, Ralf Mueller
wiley   +1 more source

β‐Cell glucokinase expression was increased in type 2 diabetes subjects with better glycemic control 血糖控制较好的2型糖尿病患者β细胞葡萄糖激酶表达增加

Journal of Diabetes, Volume 15, Issue 5, Page 409-418, May 2023., 2023
Highlights A significant upregulation of glucokinase (GCK) expression was found in type 2 diabetes (T2D) subjects with adequate glucose control, but such increase was undetected in T2D with poor glycemic control. A strong positive correlation between GCK levels and spliced X‐box binding protein 1 (XBP1s)/activating transcription factor 4 (ATF4 ...
Jingwen Liu, Hui Fu, Fuyun Kang, Guang Ning, Qicheng Ni, Weiqing Wang, Qidi Wang   +6 more
wiley   +1 more source

A randomised controlled trial testing the rebound‐preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis

Veterinary Dermatology, Volume 34, Issue 2, Page 99-106, April 2023., 2023
Background – A rebound of pruritus occasionally occurs after oclacitinib dose reduction in dogs with atopic dermatitis (AD). Objectives – To determine whether an initial 4‐day course of prednisolone decreases the probability of a pruritus rebound after reducing the frequency of oclacitinib administration.
Thierry Olivry, Viktorija Lokianskiene, Alejandro Blanco, Pablo Del Mestre, Kerstin Bergvall, Luc Beco   +5 more
wiley   +1 more source

Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases

Veterinary Dermatology, Volume 34, Issue 1, Page 53-58, February 2023., 2023
Background – The treatment of canine chronic cutaneous lupus erythematosus (CCLE) variants generally requires immunosuppression, which often results in potentially severe adverse effects. Janus kinase inhibitors, like oclacitinib, might be a valuable treatment option due to their rapid inhibition of the action of interferons known to be relevant in the
Richard G. Harvey, Alla Olivrī, Tatiana Lima, Thierry Olivry   +3 more
wiley   +1 more source

Yogliptin monotherapy in type 2 diabetes: A 12‐week randomized, double‐blind, placebo‐controlled phase II study 优格列汀单药治疗2型糖尿病:一项12周随机、双盲、安慰剂对照的II期研究

Journal of Diabetes, Volume 14, Issue 12, Page 822-830, December 2022., 2022
Highlights Yogliptin at 200, 300, and 400 mg significantly improves glycemic control in diabetics with suboptimal control. Yogliptin at all doses was safe in type 2 diabetic patients. Abstract Background The new xanthine dipeptidyl peptidase‐4 inhibitor yogliptin has exhibited excellent hypoglycemic activity in experimental disease models.
Xin Wang, Ying Wang, Xiaolan Yong, Bojun Wu, Zilin Sun, Ning Lou, Qing Wen, Yufang Zhang, Shiyun Li, Jiarui Li, Yan He, Jinluo Cheng, Xiangdong Zhong, Jing Shen, Wenying Yang   +14 more
wiley   +1 more source

DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs DUAL I China:在一项对未服用口服降糖药物的中国2型糖尿病患者进行的随机试验中, IDegLira与其单独成分相比改善了血糖控制

Journal of Diabetes, Volume 14, Issue 6, Page 401-413, June 2022., 2022
Highlights Insulin degludec/liraglutide (IDegLira) has good efficacy and tolerability in Chinese adults with type 2 diabetes not controlled on oral antidiabetic drugs. IDegLira provides the clinical advantages of insulin and glucagon‐like peptide 1 receptor agonists, improving glycemic control while reducing the main adverse effects of insulin (weight ...
Weiqing Wang, Bue F. Ross Agner, Bin Luo, Lei Liu, Ming Liu, Yongde Peng, Shen Qu, Karolina Amelia Stachlewska, Guixia Wang, Guoyue Yuan, Qiu Zhang, Guang Ning   +11 more
wiley   +1 more source

Evaluation of the effects of chlorhexidine digluconate with and without cBD103 or cCath against multidrug‐resistant clinical isolates of Staphylococcus pseudintermedius

Veterinary Dermatology, Volume 33, Issue 1, Page 17-e6, February 2022., 2022
Background – Because of the increased incidence of multidrug‐resistant (MDR) bacteria, the use of disinfectants over antibiotics has been encouraged. However, the interactions between disinfectants and host local immunity are poorly understood. Objective – To assess the effects of chlorhexidine digluconate (Chx), with and without selected host defence ...
Domenico Santoro, Lopamudra Kher, Vanessa Chala, Christelle Navarro   +3 more
wiley   +1 more source

Immune‐checkpoint inhibitor‐associated diabetes compared to other diabetes types ‐ A prospective, matched control study 免疫检查点抑制剂相关糖尿病与其他糖尿病类型的比较‐‐一项前瞻性配对对照研究

Journal of Diabetes, Volume 13, Issue 12, Page 1007-1014, December 2021., 2021
Highlights This prospective study compares 15 patients with immune‐checkpoint induced diabetes mellitus (CPI‐DM) with a propensity score matched cohort of patients with other diabetes types. Diabetic ketoacidosis at onset and autoimmune comorbidity is more frequent in CPI‐DM patients. This can be avoided by regular glucose measurements and education on
Sascha R. Tittel, Katharina Laubner, Sebastian M. Schmid, Stefan Kress, Sigrun Merger, Wolfram Karges, Frank J. Wosch, Marcus Altmeier, Marianne Pavel, Reinhard W. Holl, DPV Initiative   +10 more
wiley   +1 more source